KBC Group’s RxSight RXST Stock Holding History

KBC Group’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,107	Closed	-$53K	–	1800
2025 Q1	$53K	Hold	2,107	–	–	﹤0.01%	1775
2024 Q4	$72K	Buy	2,107 +875	+71%	+$39.5K	﹤0.01%	1720
2024 Q3	$61K	Buy	1,232 +479	+64%	+$24.5K	﹤0.01%	1625
2024 Q2	$45K	Buy	+753	New	+$43K	﹤0.01%	1680

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KBC Group's RXST Position: Q2 2025 in Review

KBC Group sold out of RxSight (RXST) in Q2 2025, closing a stake of 2,107 shares — an estimated $53K sold.

KBC Group first reported a position in RXST in Q2 2024 and held it in 4 quarters. The position peaked at $72K in Q4 2024. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

KBC Group reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
KBC Group sold 2,107 RxSight shares in Q2 2025, an estimated $53K.
KBC Group first reported a position in RxSight in Q2 2024 and held it in 4 quarters.
KBC Group's RxSight position peaked at $72K in Q4 2024.
174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on KBC Group's 13F filing for Q2 2025, filed 8 Aug 2025.